trending Market Intelligence /marketintelligence/en/news-insights/trending/rl9ffgxvzwdbhf_elmmyeq2 content esgSubNav
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it failed to comply with Nasdaq's $1 minimum bid price per common share.

The company has 180 calendar days, or until Feb. 25, 2019, to regain compliance.

The current notice has no immediate effect on the company's listing.

New Jersey-based ContraVir Pharmaceuticals develops antiviral drugs with a focus on hepatitis B.